Clinical insights for cancer outcomes in renal transplant patients (Q37811514)

23 August 2017

title

Clinical insights for cancer outcomes in renal transplant patients (English)

1 reference

23 August 2017

J Alberú

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Transplantation Proceedings

23 August 2017

published in

1 reference

23 August 2017

1 reference

23 August 2017

issue

9 Suppl

1 reference

23 August 2017

page(s)

S36-40

1 reference

Improved graft survival after renal transplantation in the United States, 1988 to 1996

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Cancer mortality in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Causes of death after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Cancer incidence after immunosuppressive treatment following kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Cancer after kidney transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Identifying High Risk Groups and Quantifying Absolute Risk of Cancer After Kidney Transplantation: A Cohort Study of 15 183 Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Malignancy in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Malignancies complicating organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Lymphomas after solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Skin cancers after organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Malignancy after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Azathioprine and UVA light generate mutagenic oxidative DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.006

10.1016/J.TRANSPROCEED.2010.07.006

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference